SCHEMBL3816037

SCHEMBL3816037

NC(=O)OC1(c2ccc(C#Cc3ccccc3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 6/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ GRM5 P41594 5/20 0.39
▸ MAPT P10636 2/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ APP P05067 1/20 0.38
▸ HNF4A P41235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572169 0.85 AKR1C1 (0.42) MAPTMEN1KMT2A
SCHEMBL11289324 0.78 AKR1C1 (0.48) MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL26135641 0.78 AKR1C1 (0.44) MEN1KMT2A
SCHEMBL11275197 0.77 AKR1C1 (0.47) MEN1KMT2ASMN1; SMN2
SCHEMBL11736962 0.76 NPC1 (0.45) FFAR1NPC1RAB9AGRM5MAPT
SCHEMBL4849593 0.75 PARP15 (0.41) NPC1RAB9ALMNACA1CA2
SCHEMBL2720401 0.75 CA1 (0.37) RAB9AMEN1KMT2ASMN1; SMN2CA12
SCHEMBL28108261 0.75 CA1 (0.36) LMNACA1CA2
SCHEMBL28755810 0.75 HDAC4 (0.41) —
SCHEMBL23647372 0.74 OPRM1 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391623-A1 INHIBITORS OF AKT ACTIVITY Merck Sharp & Dohme Corp. (US) 2011-12-07 — — EP disclosed
WO-2010088177-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-08-05 — — WO disclosed
Send feedback